UFIS-SWE-IG
0.1.0 - ci-build

UFIS-SWE-IG, published by UNICOM. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/ufis-swe-ig/ and changes regularly. See the Directory of published versions

Example RegulatedAuthorization: SimvastatinBluefish-20mg-Tablet-SE-BS-RA

Generated Narrative: RegulatedAuthorization SimvastatinBluefish-20mg-Tablet-SE-BS-RA

identifier: http://ema.europa.eu/fhir/marketingAuthorizationNumber/26678

subject: MedicinalProductDefinition: identifier = http://ema.europa.eu/fhir/mpId#SE-100002566-00026678,http://ema.europa.eu/fhir/eurdId#2709; domain = Human use; status = Current; combinedPharmaceuticalDoseForm = Film-coated tablet; indication = Hypercholesterolaemia Treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (such as exercise, weight reduction) is inadequate. Treatment of homozygous familial hypercholesterolaemia (HoFH) as an adjunct to diet and other lipid-lowering treatments (e.g. LDL-apheresis) or if such treatments are not appropriate. Cardiovascular prevention Reduction of cardiovascular mortality and morbidity in patients with manifest atherosclerotic cardiovascular disease or diabetes mellitus, with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors and other cardioprotective therapy (see section 5.1).; legalStatusOfSupply = Medicinal product subject to medical prescription; classification = simvastatin

type: Marketing Authorisation

region: Kingdom of Sweden

status: Valid

statusDate: 2008-10-31

holder: Organization Bluefish Pharmaceuticals

Cases

-TypeDate[x]
*First Authorisation2008-10-31